TY  - CHAP
M1  - Book, Section
TI  - Treatment of Non–Small-Cell Lung Cancer: Chemotherapy
A1  - Carr, Laurie L.
A1  - Jett, James R.
A2  - Grippi, Michael A.
A2  - Elias, Jack A.
A2  - Fishman, Jay A.
A2  - Kotloff, Robert M.
A2  - Pack, Allan I.
A2  - Senior, Robert M.
A2  - Siegel, Mark D.
PY  - 2015
T2  - Fishman's Pulmonary Diseases and Disorders, 5e
AB  - Historically,  lung  cancer  is  associated  with  high  mortality  rates  and  little  effective  therapy.  Because  this  disease  predominately  affects  those  of  advanced  age  with  significant  comorbidities,  treatment  can  be  difficult  to  deliver  safely  with  manageable  adverse  effects.  All  of  these  factors  can  lead  to  a  sense  of  futility  among  clinicians  and  patients  when  discussing  lung  cancer  therapy.  However,  in  the  last  several  years  novel  therapies  have  emerged  to  make  lung  cancer  therapy  better  tolerated  and  more  effective,  even  among  those  with  significant  comorbidities.  The  introduction  of  better-tolerated  cytotoxic  chemotherapy  and  targeted  agents  has  made  lung  cancer  therapy  tenable  for  many  more  patients.  In  addition,  the  improved  response  rates  seen  by  matching  targeted  drugs  to  specific  genetic  alterations  driving  tumor  growth  have  led  to  improved  quality  of  life  and  survival  among  patients  with  these  specific  tumors.  Thus,  although  the  morbidity  and  mortality  of  lung  cancer  remain  high,  novel  approaches  to  therapy  and  improved  supportive  care  have  begun  to  make  a  significant  impact  in  the  burden  of  this  disease.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1122367525
ER  -